alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,226–1,250 of 1,489 studies in Treatments (page 50 of 60) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Treatments” covers

Treatments — Drug and non-drug treatment research — what was tested, in whom, and what changed — plus the approvals and coverage decisions that followed.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Dementia and geriatric cognitive disorders 2008-12-04

36% of practitioners reported not having used therapies for medical conditions other than dementia in patients with AD for reasons of limited compliance in these patients. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain and behavior 2013-01-11

The combination of memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, with an acetylcholinesterase inhibitor (AChEI) is the current standard of care in Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of the neurological sciences 2004-11-15

Cerebrovascular disease (CVD), as well as secondary ischemic brain injury from cardiovascular disease, are common causes of dementia and cognitive decline in the elderly. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

✓ Peer-reviewed alzhub usefulness score 38 out of 100. International journal of geriatric psychiatry 2004-06

The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective

✓ Peer-reviewed alzhub usefulness score 37 out of 100. International psychogeriatrics 2007-04-16

Based on efficacy and safety data, several drugs have been approved for symptomatic improvement of dementia of the Alzheimer type and one for the symptomatic improvement of dementia associated with Parkinson's disease. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer disease and associated disorders 1998-01-01

These studies have shown that PPF 300 mg t.i.d. is safe and well tolerated when taken on an empty stomach 1 h before meals. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Intervention for a Digital, Cognitive, Multi-Domain Alzheimer Risk Velocity Study: Protocol for a Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 37 out of 100. JMIR research protocols 2022-02-04

The intervention in the Digital, Cognitive, Multi-domain Alzheimer Risk Velocity is uniquely designed to reduce the risk of AD through a web-based health coaching experience that addresses the modifiable lifestyle-based risk factors. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Physiotherapy research international : the journal for researchers and clinicians in physical therapy 2021-02-15

Improvements in the aspects evaluated are expected in the IG compared to CG. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lecanemab use for early Alzheimer disease in Canada

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Canadian Medical Association Journal 2026-06-28

Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a debated model of Alzheimer disease pathogenesis.1 Only patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease are eligible for lecanemab treatment. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current Alzheimer research 2017-01-01

The authors of this mini-review list the key benefits (e.g., positive results of the reviewed randomized clinical trials studies for the improvement of cognitive decline in AD) and limitations (e.g., low awareness of benefits of TCM in Europe) of Chinese medicine therapy for the treatment of AD. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopes

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

Within the limitations of measuring in vitro equilibrium binding activity of in‐house recombinant antibodies to aqueously extracted Aβ from human postmortem brain tissue, we could not discern a population of Aβ aggregates ( e.g . protofibrils) accessible to one antibody but not the other two. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s Research & Therapy 2025-04-11

The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June 2023. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropathology and Applied Neurobiology 2025-06-01

Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which resemble or are identical to human structures observed in sporadic and familial cases of Alzheimer's disease, including a case with the Arctic (E22G) mutation. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-04-23

Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%. 4 key findings →

Design: narrative review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Oral Microbiome and Its Emerging Role in Alzheimer\'s Disease: A Comprehensive Review

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Acute Care Trauma and Emergency Medicine 2026-06-29

Alzheimer's disease (AD) affects ~55 million people globally and is projected to rise steeply with population ageing. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Neuropathology & Experimental Neurology 2026-07-23

TDP-43 proteinopathies encompass frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), amyotrophic lateral sclerosis (ALS-TDP), and limbic predominant age related TDP-43 encephalopathy neuropathological change (LATE-NC). 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multi‐Targeting Makrozyklische Peptide als Nanomolare Inhibitoren der Selbst‐ und Kreuznukleation der Amyloiden Selbstassemblierung von α‐Synuclein

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Angewandte Chemie 2025-01-17

Die amyloide Selbstassemblierung von α‐Synuclein (αSyn) wird mit der Pathogenese der Parkinson‐Krankheit (PD) in Verbindung gebracht. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Cell 1988-02-01

Two approaches--molecular cloning and immunochemical analysis--have identified one of the components of Alzheimer's disease amyloid deposits as the serine protease inhibitor alpha 1-antichymotrypsin. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed